Keystone Symposia

Eldorado Hotel & Spa Floorplan

NOTES:
This meeting will be conducted in English.

All programs are subject to change. Check this site for updates.

Download Flyer
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, June 25 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, June 28 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Thursday, June 29 in order to fully experience the meeting.

SUNDAY, JUNE 25

16:00—20:00
Arrival and Registration

Cava Santa Fe
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Cava Santa Fe

MONDAY, JUNE 26

07:00—08:00
Breakfast

Anasazi Ballroom
08:00—09:00
Welcome and Keynote Address (Joint)

Eldorado A/B
* Merry L. Lindsey, Meharry Medical Center, USA

* Marlene Rabinovitch, Stanford University, USA

Elizabeth M. McNally, Northwestern University, USA
Genetic Determinants of Heart Failure

Coffee Break

09:30—11:15
Cell-Cell Cross-Talk

Eldorado A
* Merry L. Lindsey, Meharry Medical Center, USA

* Upendra Chalise, University of Nebraska Medical Center, USA

Gillian A. Gray, University of Edinburgh Centre for Cardiovascular Science, UK
Intracellular Glucocorticoid Regeneration as a Novel Target to Regulate Infarct Repair and Progression to Heart Failure

Karin Sipido, KU Leuven, Belgium
Myofibroblast Modulation of Cardiac Myocyte Physiology

Jennifer E. Van Eyk, Cedars-Sinai, USA
Harnessing Proteomics for Novel HF Diagnostics and Therapies

Jason Maynes, Hospital for Sick Children, Canada
Short Talk: Inherent Inflammatory Characteristics Determine Repair and Transferable Benefit of Cardiac Progenitor Cells in Patients with Congenital Heart Disease

09:30—11:30
The Metabolic Basis of Pulmonary Arterial Hypertension Beyond Glycolysis

Eldorado B
Marlene Rabinovitch, Stanford University, USA
Integrating Pathways in Pulmonary Hypertension

Sadis Matalon, University of Alabama at Birmingham, USA
Oxidative Mitochondrial DNA Injury is a Key Contributor to the Development of Chemical Lung Injury

Stephen L. Archer, Queen's University, Canada
The Role of Altered Mitochondrial Dynamics and Metabolism in Pulmonary Hypertension

Michela Noseda, Imperial College London, UK
Single Cell and Spatial Transcriptomics State-of-the-heart

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Anasazi Ballroom
13:00—22:00
Poster Viewing

Anasazi Ballroom
14:30—16:30
Workshop 1

Eldorado A
* Nicholas W. Chavkin, University of Virginia, USA

* Mikito Takefuji, Nagoya University School of Medicine, Japan

Thomas Martin, University of Colorado Boulder, USA
Activation of FOXO1-dependent Autophagy Mediates Regression of Cardiac Hypertrophy

Preethy Parthiban, University of Minnesota- Twin Cities, USA
Macrophage-derived CCL24 Drives Impaired Cardiomyocyte Relaxation and Systolic Dysfunction During Heart Failure

Upendra Chalise, University of Nebraska Medical Center, USA
Big Data Guided Analysis Reveals Unique Cardiac Remodeling Trajectories by Sex After Myocardial Infarction

Benjamin D. McNair, University of Wyoming, USA
Distinct Mechanisms of Aging in the Right and Left Ventricles

Bryana N. Harris, University of Virginia, USA
Dynamic Map Illuminates Hippo Module Crosstalk Driving Cardiomyocyte Proliferation

Karin J. Bosma, Vanderbilt University Medical Center, USA
Modulation of Prostaglandin E2 Receptors EP3 and EP4 as a Novel Therapeutic Strategy to Improve Cardiac Function in Type 2 Diabetes

Alexa Corker, Medical University of South Carolina, USA
PTSD has a Negative Impact on Cardiac Homeostasis

Abraham L. Bayer, Tufts Graduate School of Biomedical Sciences, USA
T-Cell MyD88 is a Novel Regulator of Cardiac Fibrosis through Modulation of T-cell Activation

14:30—16:30
Workshop 1: Imaging and Biomarkers of Disease Altering Therapies

Eldorado B
* Christopher Rhodes, Imperial College London, UK

* Wendy K. Chung, Columbia University, USA

S M Riajul Wahab, University of Texas at El Paso, USA
Identifying the Role of Prion-like Protein Doppel as a Novel Mediator of Pulmonary Arterial Hypertension

Claudia Mickael, University of Colorado Denver, USA
Classical Dendritic Cells Drive and Maintain Hypoxia-Induced Pulmonary Hypertension

Micheala A. Aldred, Indiana University, USA
Cybrid Analysis Delineates Nuclear and Mitochondrial Contributions to Oxidative Stress in Pulmonary Arterial Hypertension

Cassidy Delaney, University of Colorado, USA
Platelets Participate in Regulation of the Early Immune Response in Experimental PH

Slaven Crnkovic, Medical University of Graz, Austria
Defining Cell-type Specific Disease States in Pulmonary Hypertension

Jingbo Dai, Northwestern University, USA
The RNA m6A Demethylase, FTO, Regulates Vascular Remodeling in the Pathogenesis of Pulmonary Arterial Hypertension

Bin Liu†, University Of Arizona, USA
Fatty Acid-binding Proteins Promote Pulmonary Arterial Hypertension via Glycolysis

Caitlin Lewis, University of Colorado, USA
Extracellular Superoxide Dismutase Affects Interstitial Macrophage Accumulation, Reprogramming and Hyaluronan Binding during Pulmonary Hypertension

16:30—17:00
Coffee Available

Concourse
17:00—19:00
Cell Heterogeneity in Heart Failure

Eldorado A
* Gillian A. Gray, University of Edinburgh Centre for Cardiovascular Science, UK

* Preethy Parthiban, University of Minnesota- Twin Cities, USA

Amy D. Bradshaw, Medical University of South Carolina, USA
Fibroblast Activation Profiles in Pressure Overload

Jennifer Davis, University of Washington, USA
Mechanical Signaling Networks that Program Fibroblasts

Taben Hale, University of Arizona, USA
Sub-Populations of Resident Cardiac Fibroblasts in Hypertension: Taking a Census

Alessandra Pasut, KULeuven, Belgium
Short Talk: Metabolic Heterogeneity of Endothelial Cells in HFpEF

Richard Keith Babbs, Keros Therapeutics, USA
Short Talk: RKER-012, A Novel Modified ActRIIB Ligand Trap, Attenuated Cardiac Hypertrophy, Fibrosis, and Cardiovascular Remodeling in a Transaortic Constriction Model of Heart Failure

17:00—19:00
How Epigenetic Changes and RNA Translation Govern Disease Susceptibility

Eldorado B
Sebastien Bonnet, Université Laval, Canada
Epigenetics Targets in PAH: BRD4 and ACLY Novel's Targets for Vascular Remodeling

Soni Savai Pullamsetti, Max-Planck-Institute for Heart and Lung Research, Germany
The Suppressor Function of lnc RNAs in Pulmonary Hypertension

Chen-Shan Julia Woodcock, University of Pittsburgh, USA
Short Talk: RNA Editing Deficiency Induces Pulmonary Endothelial Pathophenotypes and Drives Pulmonary Hypertension

Cheng-Jun Hu, University of Colorado Denver, USA
Short Talk: Pulmonary Vascular Fibroblasts Are Epigenetically Primed for Inflammatory Responses

YouYang Zhao, Northwestern University-Lurie Children's Hospital of Chicago, USA
Short Talk: Endothelial Cell-targeted Nanoparticle Delivery of CRISPR/Cas9 Plasmid DNA Disrupts Endothelial HIF-2a in Adult Rats and Inhibits Experimental PAH: Towards Genome Editing Therapy of PAH

Yi Peng, Ann & Robert H. Lurie Children's Hospital of Chicago, USA
Short Talk: Therapeutic Genome Editing of Endothelial Fabp4 Inhibits Pulmonary Arterial Hypertension in Rats

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Anasazi Ballroom
19:30—22:00
Poster Session 1

Anasazi Ballroom

TUESDAY, JUNE 27

07:00—08:00
Breakfast

Anasazi Ballroom
07:30—08:30
Poster Setup

Anasazi Ballroom
08:00—19:00
Poster Viewing

Anasazi Ballroom
08:00—11:00
Cardiopulmonary Crossroads (Joint)

Eldorado A/B
* Zamaneh Kassiri, University of Alberta, Canada

Tim Lahm, National Jewish Health, USA
Sex as a Determinant of Right Ventricular Dysfunction in Pulmonary Hypertension

Tami Martino, University of Guelph, Canada
Circadian Rhythms and HF Chronotherapy

Coffee Break

Bradley Maron, University of Maryland School of Medicine, USA
Individualized Interactomes Advance Precision Medicine in Heart Failure Syndromes

Crystal Ripplinger, University of California, Davis, USA
The Nervous Heart: Autonomic Remodeling Post-MI

Yongneng Zhang, University of Alberta, Canada
Short Talk: A Critical Contribution of Cardiac Myofibroblasts in RV Failure and the Role of a UCP2 SNP as a Biomarker Identifying PAH Patients Predisposed to RV Decompensation

Kenzo Ichimura, Stanford University, USA
Short Talk: 3D Deep Tissue Imaging Reveals Complex Remodeling of the Microvasculature in Right Heart Failure

11:00—12:30
Lunch

Anasazi Ballroom
12:00—14:30
Poster Session 2

Anasazi Ballroom
15:00—16:30
Workshop 2

Eldorado A
* Thomas Martin, University of Colorado Boulder, USA

* Alexa Corker, Medical University of South Carolina, USA

Thirupura Sundari Shankar, University of Utah, USA
Adipocyte Enhancer Binding Protein 1 as a Novel Therapeutic Target to Combat Fibrosis in Heart Failure

Mikito Takefuji, Nagoya University School of Medicine, Japan
Cardiac Atypical Kinase Improves Left Ventricular Diastolic Dysfunction in Heart Failure with Preserved Ejection Fraction

Mohit Kumar, Regeneron Pharmaceuticals, Inc., USA
Characterization of Right Ventricle Involvement in MYBPC3-linked Hypertrophic Cardiomyopathy

Patricia Perez-Bonilla, Pfizer Inc., USA
Heart Rate Variability and Chronotropic Incompetence as Prognostic Markers in a HFpEF Preclinical Model

Nicholas W. Chavkin, University of Virginia, USA
Hematopoietic Loss of the Y Chromosome Promotes Cardiac Fibrosis through Epigenetic Regulation of Autosomal Genes in Monocytes and Macrophages

14:30—16:30
Workshop 2: Narrowing the Gap Between Discovery and Therapy in Pulmonary Hypertension

Eldorado B
* Stephen L. Archer, Queen's University, Canada

* Sebastien Bonnet, Université Laval, Canada

Ke Yuan, Boston Children's Hospital, USA
Deficiency of Smooth Muscle ADAR1 RNA Editing Exacerbates Vascular Remodeling and Pulmonary Hypertension

Sarasa Isobe, Stanford University, USA
Loss of BMPR2 Links Unrepaired DNA Damage to Reduced FOXF1 and Pulmonary Arterial Hypertension

Tamanna Islam, University of Texas at El Paso, USA
Bioengineering Models to Study Cell-Specific Durotaxis in Pulmonary Arterial Hypertension

Madelyn Blake, University of Minnesota Medical School, USA
Microbiota Transplant Therapy is Safe and Feasible in Patients with Pulmonary Arterial Hypertension

Emily J. Tsai, Columbia University Vagelos College of Physicians & Surgeons, USA
In vivo Cardiac Myocyte-specific Knockdown of Wipi1 Prevents Decompensation of the Pressure-overloaded Right Ventricle

Yingjie Chen, University of Mississippi Medical Center, USA
Natural Killer Cells Regulate Heart Failure-induced Cardiopulmonary Inflammation, Pulmonary IFN-γ Production, and Pulmonary Remodeling

Pontian Adogamhe, Indiana University School of Medicine, USA
NAMPT Overexpression Decreases Sirt 3 Deacetylase Activity in Human Pulmonary Artery Endothelial Cells

Olin Liang, Brown University, USA
Targeting RUNX1 as a Novel Treatment Modality for Pulmonary Arterial Hypertension

16:30—17:00
Coffee Available

Concourse
17:00—19:00
Cell Responses to Myocardial Injury and Growth

Eldorado A
* Taben Hale, University of Arizona, USA

* Chi Fung Lee, Oklahoma Medical Research Foundation, USA

Leslie A. Leinwand, University of Colorado Boulder, USA
Diet and Exercise Effects on Cardiac Growth

Kristine Deleon-Pennell, Medical University of South Carolina, USA
T Cell Regulation of MI Remodeling

Kathleen Woulfe, University of Colorado Anschutz Medical Campus, USA
Short Talk: Age-specific Decreases in Sarcomeric Acetylation Modulates Myofilament Function in Skeletal and Cardiac Muscle

Ann Chiao, Oklahoma Medical Research Foundation, USA
Short Talk: Aging Exacerbates Diastolic Dysfunction and Proteostatic Imbalance in Heart Failure with Preserved Ejection Fraction

17:00—19:00
Using Big Data to Understand Complex Disease

Eldorado B
Christopher Rhodes, Imperial College London, UK
The Significance of Noncoding Variants in Pulmonary Hypertension

Wendy K. Chung, Columbia University, USA
Penetrance of Mutations in Pediatric Pulmonary Hypertension

Jose Gomez-Arroyo,, University of Cincinnati, USA
Role of FOXF1 in the Pathobiology of Pulmonary Arterial Hypertension

Gabriel Maldonado-Velez, Indiana University School of Medicine, USA
TBX4 Loss-of-function within the Embryonic Lung Mesenchyme Disrupts Lung Alveolar Development and Increases Susceptibility to Pulmonary Hypertension

19:00—20:00
On Own for Dinner
No registration fees are used to fund alcohol served at this function.


WEDNESDAY, JUNE 28

07:00—08:00
Breakfast

Anasazi Ballroom
08:00—11:00
Cardiometabolic Aspects of HF

Eldorado A
* Ann Chiao, Oklahoma Medical Research Foundation, USA

* Abraham L. Bayer, Tufts Graduate School of Biomedical Sciences, USA

Rebecca Ritchie, Monash Institute of Pharmaceutical Sciences, Australia
Diabetic Effects on Cardiac Remodeling

Susan E. Howlett, Dalhousie University, Canada
The Many Effects of Aging and Frailty on the Heart

Coffee Break

Helen E. Collins, University of Louisville, USA
Mechanisms Contributing to Pregnancy-Induced Cardiac Growth

Chi Fung Lee, Oklahoma Medical Research Foundation, USA
Short Talk: SARM1 Deficiency Prevents NAD Decline, Improve Mitochondrial and Cardiac Function in Cardiometabolic Disease

Kayla J. Rayford, Meharry Medical College, USA
Short Talk: Trypanosoma Cruzi Alters Expression of piRNAs That Target Profibrotic and Inflammatory Molecules During Acute Infection of Primary Human Cardiac Fibroblasts

Adaysha Williams, Medical College of Wisconsin, USA
Short Talk: High Inorganic Phosphate Treatment Reduces Rat Neonatal Cardiomyocyte Viability

08:00—11:00
Using Biology to Guide Vascular Regeneration

Eldorado B
Celeste M. Nelson, Princeton University, USA
Building Pulmonary Trees: Insights from the Embryo

Vinicio de Jesus Perez, Stanford University, USA
Restoring Normal Microvessels in Pulmonary Hypertension

Coffee Break

Stella Kourembanas, Children's Hospital Boston, Harvard Medical School, USA
Vascular and Lung Regeneration and Exosomes

Rubin M. Tuder, University of Colorado Hospital - Anschutz, USA
Disease Heterogeneity and the Challenges in Evaluating Therapies for a Complex Disease

David B. Frank, Children's Hospital of Philadelphia, USA
Ontogeny and Cellular Heterogeneity in Pulmonary Vascular Development and Disease

11:00—17:00
On Own for Lunch

15:00—16:30
Career Roundtable (Joint)

DeVargas
16:30—17:00
Coffee Available

Concourse
17:00—18:45
Pharma Targets for Heart Failure

Eldorado A
* Helen E. Collins, University of Louisville, USA

* Yongneng Zhang, University of Alberta, Canada

Zamaneh Kassiri, University of Alberta, Canada
Metalloproteases Make It or Break It

Rachel J. Roth Flach, Pfizer Inc., USA
Metabolic Targets for Heart Failure

Michael Dunn, Regeneron Pharmaceuticals, USA
Sustained Vasodilation in Preclinical Species and Humans by an Investigational Agonist Monoclonal Antibody to a Membrane-bound Guanylate Cyclase Receptor, Natriuretic Peptide Receptor 1

Aina Hirofuji, Asahikawa Medical University, Japan
Short Talk: Mycn Induces Cardiomyocyte Mitosis in Adult Mice

17:00—18:45
The Inflammatory Basis of Pulmonary Hypertension

Eldorado B
Harry Karmouty-Quintana, University of Texas Health Science Center, USA
RNA Translation and the Proteome of Pulmonary Hypertension

Kurt R. Stenmark, University of Colorado Denver, USA
The Interplay Between Fibroblasts and Monocytes in Pulmonary Hypertension

Simon Bousseau, National Jewish Health, USA
Short Talk: 17β-estradiol Regulates Angiogenesis and Right Ventricle Endothelial Cell Metabolism in Pulmonary Arterial Hypertension

Tadanori Mammoto, Medical College of Wisconsin, USA
Short Talk: Endothelial Senescence in Pulmonary Hypertension

Benjamin Korman, University of Rochester, USA
Short Talk: Single Cell RNA Sequencing of Mice with TNF-mediated Pulmonary Hypertension Demonstrates Marked Changes in Endothelial and Mesenchymal Cell Populations and Aberrant BMP Signaling

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Eldorado A
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Eldorado B
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Anasazi Ballroom

THURSDAY, JUNE 29

08:00—08:00
Departure


*Session Chair †Invited, not yet responded.


Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

AstraZeneca Ionis Pharmaceuticals, Inc.
Merck & Co., Inc. Novo Nordisk A/S

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13HL168861-01

Funding for this conference was made possible (in part) by 1R13HL168861-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: John Monson, Director of Corporate Relations, Email: johnm@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179